SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 0.8%

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)’s stock price traded down 0.8% during mid-day trading on Monday . The stock traded as low as $1.07 and last traded at $1.25. 984,937 shares were traded during mid-day trading, a decline of 14% from the average session volume of 1,146,706 shares. The stock had previously closed at $1.26.

Analysts Set New Price Targets

Separately, Royal Bank of Canada upgraded SELLAS Life Sciences Group to a “moderate buy” rating in a research note on Monday, June 24th.

SELLAS Life Sciences Group Stock Down 0.8 %

The firm has a market capitalization of $72.19 million, a PE ratio of -1.14 and a beta of 2.39. The stock’s fifty day simple moving average is $1.25 and its 200 day simple moving average is $1.27.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. On average, analysts predict that SELLAS Life Sciences Group, Inc. will post -0.55 EPS for the current year.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Anson Funds Management LP purchased a new position in SELLAS Life Sciences Group during the first quarter valued at approximately $4,881,000. Armistice Capital LLC bought a new stake in shares of SELLAS Life Sciences Group during the 4th quarter valued at $869,000. Opus Capital Group LLC raised its position in shares of SELLAS Life Sciences Group by 48.6% during the 1st quarter. Opus Capital Group LLC now owns 200,600 shares of the company’s stock valued at $203,000 after purchasing an additional 65,600 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of SELLAS Life Sciences Group during the 2nd quarter valued at $39,000. 17.38% of the stock is owned by hedge funds and other institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.